Impact of Immunosuppressive Drug Concentrations on Microvascular Inflammation, Negative Donor‐Specific Antibodies, and C4d‐Negative Status in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70112 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Yoichi Kakuta and 9 co-authors. Institution: Department of Urology, Osaka Graduate School of Medicine, Suita, Osaka, Japan. Major MEDLINE topics: Kidney Transplantation, Immunosuppressive Agents, Graft Rejection, Isoantibodies. Cited 3 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Introduction
This study investigated the impact of immunosuppressive drug concentrations on microvascular inflammation (MVI) in kidney transplant recipients with negative donor‐specific antibodies (DSA) against human leukocyte antigen (HLA) and negative C4d deposition in peritubular capillaries.
Methods
We analyzed data from 268 living kidney transplant recipients at the Department of Urology, University of Osaka, Japan. Patients received immunosuppressive therapy comprising extended‐release tacrolimus, mycophenolate mofetil (MMF), and/or everolimus, with or without steroids. Graft biopsies were routinely performed at 3, 12, 36 and 60 months post‐surgery.
Results
No significant differences were observed between the MVI+DSA‐C4d‐ and MVI‐DSAC4d groups regarding graft survival rates (95.5% vs. 96.6%, p = 0.772) or patient survival rates (95.7% vs. 95.9%, p = 0.735). Lower tacrolimus and everolimus concentrations were significantly associated with an increased risk of MVI+DSA‐C4d‐ (tacrolimus: OR, 0.169; 95% CI, 0.055–0.515; p = 0.002; everolimus: OR, 0.386; 95% CI, 0.171–0.874; p = 0.022). In contrast, MPA concentration was not significantly associated with MVI+DSA‐C4d‐ (OR, 0.994; 95% CI, 0.554–1.780; p = 0.984). Steroid discontinuation did not significantly impact the risk of MVI+DSA‐C4d‐ (OR, 1.980; 95% CI, 0.318–12.000; p = 0.470).
Conclusion
Lower trough levels of tacrolimus and everolimus correlated with a higher incidence of antibody‐independent MVI, supporting the need for tailored immunosuppressive regimens in kidney transplantation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, Osaka Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Nephrology, Osaka Graduate School of Medicine, Suita, Osaka, Japan.
ORCID profiles: Yoichi Kakuta, Ryo Tanaka
Cite
APA
Kakuta, Y., Maegawa-Higa, Y., Matsumura, S., Fukae, S., Tanaka, R., Yonishi, H., Nakazawa, S., Namba-Hamano, T., Isaka, Y., & Nonomura, N. (2025). Impact of Immunosuppressive Drug Concentrations on Microvascular Inflammation, Negative Donor‐Specific Antibodies, and C4d‐Negative Status in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70112
Vancouver
Kakuta Y, Maegawa-Higa Y, Matsumura S, Fukae S, Tanaka R, Yonishi H, et al. Impact of Immunosuppressive Drug Concentrations on Microvascular Inflammation, Negative Donor‐Specific Antibodies, and C4d‐Negative Status in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70112
BibTeX
@article{Kakuta2025,
author = {Kakuta, Yoichi and Maegawa-Higa, Yoko and Matsumura, Soichi and Fukae, Shota and Tanaka, Ryo and Yonishi, Hiroaki and Nakazawa, Shigeaki and Namba-Hamano, Tomoko and Isaka, Yoshitaka and Nonomura, Norio},
title = {Impact of Immunosuppressive Drug Concentrations on Microvascular Inflammation, Negative Donor‐Specific Antibodies, and C4d‐Negative Status in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70112}
}
EUVIMED